Newsbytes
August 2026—Pathologists and other cross-departmental staff at Beth Israel Lahey Health, in Boston, recently used an “all for one and one for all” approach to decision-making in evaluating image-management systems for purchase.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Columns
Put It on the Board
August 2026—Roche in June launched its Axelios 1, a next-generation single-molecule sequencing platform that it says will address bottlenecks in genomics and potentially in clinical research.
Shorts on Standards
August 2026—The CAP introduced in its 2025 accreditation checklist edition GEN.20315 Risk Management, which says the laboratory’s quality management system uses a prospective risk management process. That process includes identification, control, and monitoring of risks throughout the laboratory.
From the President’s Desk
July 2026—There’s an important election coming up, and it’s not the one you’ve been hearing about on the news. Voting will begin soon for new members of the CAP’s Board of Governors, and I urge you to take part.
Clinical pathology selected abstracts
July 2026—Sepsis is a major cause of pediatric morbidity and mortality worldwide. It is difficult to measure the number of pediatric sepsis cases since most estimates are based on administrative codes, and coding practices vary by institution. Medical record review offers greater accuracy in recording pediatric sepsis diagnoses, but it is labor intensive and subject to interrater variability.
Anatomic pathology selected abstracts
July 2026—Hepatoid lung carcinomas, similar to hepatoid carcinomas of other sites, are defined as extrahepatic tumors exhibiting divergent hepatocellular differentiation. Uniquely, hepatoid carcinomas of the lung are reported to commonly express only HepPar1, which recognizes the mitochondrial enzyme carbamoyl-phosphate synthetase-1 (CPS1). HepPar1/CPS1 was recently found to accumulate in lung adenocarcinomas (LUAD) harboring STK11 mutations, presumably as a genotype-associated metabolic adaptation.
Molecular pathology selected abstracts
July 2026—Parkinson’s disease, which is characterized by loss of dopamine-producing neurons in the brain’s substantia nigra and the pathologic misfolding and accumulation of alpha-synuclein, can result in a range of motor and nonmotor symptoms that may vary by individual. The cardinal motor symptoms of Parkinson’s disease (PD) are bradykinesia (slowness of movement), resting tremor, rigidity, and postural instability. A prodromal phase of the disease can generate nonmotor symptoms, such as a reduced sense of smell years prior to the onset of cardinal motor symptoms.
Pathology informatics selected abstracts
July 2026—Apollo is a health care-scale multimodal foundation model designed to integrate longitudinal clinical data into unified virtual patient representations. It was developed by the authors using data from a major U.S. health care system and trained on approximately 25 billion clinical records from 7.2 million patients that spanned more than three decades. The data set incorporated 12 medical specialties and 28 clinical modalities, including pathology images, laboratory testing, clinical documentation, medications, and structured electronic health record data.
Q&A column
July 2026
Q. What is the recommended approach for determining the HIV status of patients who are taking HIV pre-exposure prophylaxis or have received oral PrEP within the past three months or intramuscular PrEP within the past 12 months? Read answer.
Q. Our providers pointed out that lipoprotein(a) results from different laboratories are discordant, so they asked us to bring the assay in-house. Is this a good idea? Read answer.
Newsbytes
July 2026—Dedicated training in histology is increasingly getting short shrift as many academic medical institutions nationwide move to an organ system-based teaching structure. Recognizing this trend, a group of faculty and residents at the University of Wisconsin School of Medicine and Public Health are employing creativity, a simple software program, and a bit of teamwork to boost medical students’ exposure to the specialty.